Detail akcie KemPharm Rg online

Business Summary: Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Zevra Therapeutics Inc revenues increased from $11.6M to $72.3M. Net income totaled $71.1M vs. loss of $69.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Research and development - balancing decrease of 69% to $9.4M (expense), Interest and other income increase from $2.2M to $5.2M (income).